Adcendo
Private Company
Total funding raised: $191M
Overview
Adcendo is a clinical-stage biotechnology company pioneering novel antibody-drug conjugate (ADC) therapies for cancers with significant unmet need. Its lead candidate, ADCE-D01, targeting uPARAP for soft tissue sarcoma, has entered Phase I/II trials and received FDA Fast Track designation, highlighting its potential. The company is led by a seasoned management team with direct experience in developing and commercializing multiple approved ADC drugs, positioning it strongly in the competitive oncology landscape.
Technology Platform
Focus on developing antibody-drug conjugates (ADCs) through deep understanding of novel target biology (particularly endocytic receptors like uPARAP) combined with optimized linker-payload technologies.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Adcendo competes in the crowded and fast-growing field of ADC oncology therapeutics, dominated by large pharma (e.g., AstraZeneca/Daiichi Sankyo, Gilead) and other biotech innovators. Its differentiation strategy relies on targeting novel biology (uPARAP) not addressed by existing ADCs to carve out a niche in specific sarcoma subtypes.